脑部影像和神经影像市场－全球产业规模、份额、趋势、机会及预测（按影像类型、最终用户、地区和竞争格局划分，2021-2031年）

全球脑部影像和神经影像诊断市场预计将从 2025 年的 126.4 亿美元成长到 2031 年的 184 亿美元，复合年增长率为 6.46%。

这些产品包括各种非侵入性诊断技术，例如电脑断层扫描 (CT) 和磁振造影(MRI)，旨在可视化中枢神经系统的结构和功能状态。市场的主要驱动力是神经系统疾病发病率的上升和全球人口老化，这两方面都推动了对早期、精准疾病检测的需求。例如，世界卫生组织 (WHO) 报告称，到 2024 年，全球将有超过三分之一的人口患有神经系统疾病，凸显了对专业诊断干预措施的迫切需求。

儘管存在这些成长要素，但由于购买和安装诊断成像系统的高成本，市场仍面临许多障碍。新兴经济体不完善的报销政策和熟练放射科医生的短缺，往往加剧了这一经济负担，从而限制了诊断工具的广泛应用。因此，巨额资金需求和人才短缺仍然是不同经济体广泛采用先进神经影像技术的挑战。

市场驱动因素

全球脑部影像和神经影像诊断市场的主要驱动因素是神经系统疾病和神经退化性疾病的日益普遍。全球人口老化导致中枢神经系统疾病的发生率不断上升，对支持早期疗育的先进诊断技术产生了强劲的需求。根据美国癌症协会估计，截至2025年1月，美国当年将诊断出约24,820例恶性脑或脊髓肿瘤病例。这种持续的疾病负担使得广泛使用高解析度影像系统（例如MRI和CT）来评估结构完整性并指南治疗策略成为必要，从而维持了市场需求。

同时，技术的快速发展以及人工智慧（AI）在诊断流程中的应用正显着推动市场扩张。人工智慧软体透过加快影像重建速度、提高诊断准确率和实现异常自动检测，彻底改变了神经影像学。根据AuntMinnie于2025年7月发布的报告显示，美国食品药物管理局（FDA）在2024年9月至2025年7月期间核准了核准种人工智慧医疗设备，其中放射学软体占81%。这些创新也得到了研发领域大量投资的支持。根据The Transmitter于2025年11月发布的报告显示，美国国立卫生研究院（NIH）对神经科学计划的资助预计将在2024年达到105亿美元，这将为脑造影技术的持续创新创造有利环境。

市场挑战

诊断影像系统的高昂实施和安装成本是限制全球脑部影像和神经影像市场成长的主要障碍。磁振造影(MRI) 和电脑断层扫描 (CT) 等先进诊断设备需要大量的资本支出，不仅包括初始购买费用，还包括昂贵的基础设施维修和专业维护费用。这种经济负担限制了市场渗透率，尤其是在预算紧张的小规模医疗机构和发展中地区。因此，许多机构不愿投资最新的神经影像技术，只能延长旧设备的使用寿命。

医疗机构财务状况的恶化加剧了这种经济压力，直接阻碍了它们购买新设备的能力。根据美国医院协会 (AHA) 预测，到 2024 年，医院和医疗系统的现金週转天数预计将比 2022 年初下降 28.3%，这将显着限制它们投资于新的医疗技术和基础设施的能力。流动性的减少迫使医院推迟对高成本影像设备的投资，这直接减缓了全球神经影像领域的收入成长和普及速度。

市场趋势

携带式和照护现场磁振造影系统的引入正在重塑市场格局，将神经影像检查从传统的放射科转移到加护病房和偏远地区。这种转变满足了无法安全转运至高场磁振造影设备的患者对即时中风诊断和脑部监测的迫切需求，有效克服了诸如射频屏蔽等基础设施障碍。根据2025年3月报告，Hyperfine公司在2024年售出了48套商用Swoop可携式磁振造影系统，由于医院采用率的提高，实现了17%的收入成长。这些低场、轮式系统无需专用设施，使神经影像检查更加普及，并支援在患者床边直接进行更快速的临床决策。

此外，随着医疗机构寻求降低全球氦气短缺和复杂冷却管道基础设施带来的营运风险，无氦和无液磁共振成像（MRI）技术的兴起势头强劲。这一趋势引入了密封磁体技术，该技术仅需极少量冷却剂，与传统的湿式磁铁相比，显着降低了生命週期成本和安装复杂性。根据皇家飞利浦公司2025年11月发布的新闻稿，该公司已在全球安装了超过2000套1.5T BlueSeal无氦MRI系统，迄今已节省超过600万公升液氦。这项技术革新确保了在供应中断期间的持续运作，并支持永续性目标，使无氦磁铁成为未来脑部造影设备的可靠标准。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

5. 全球脑部影像与神经影像市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 透过影像方法（功能性磁振造影（fMRI）、电脑断层扫描（CT）、正子断层扫描（PET）、脑电图（EEG）、脑磁图（MEG）、近红外线光谱（NIRS））
  • 依最终使用者（医院/诊所、门诊手术中心、其他）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美脑部影像与神经影像市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲脑部影像与神经影像市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区脑部影像诊断与神经影像市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲脑部影像和神经影像市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美洲脑造影与神经影像市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球脑部影像与神经影像市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Varian Medical Systems
• General Electric Company
• Siemens AG
• Philips Healthcare
• Toshiba Medical Systems
• Hitachi Medical Systems
• Esaote SpA
• Sanrad Medical Systems Pvt. Ltd

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Brain Imaging and Neuroimaging Market is projected to expand from USD 12.64 Billion in 2025 to USD 18.40 Billion by 2031, reflecting a compound annual growth rate of 6.46%. These products encompass a variety of non-invasive diagnostic technologies, such as computed tomography and magnetic resonance imaging, which are designed to visualize the structural and functional status of the central nervous system. The market is primarily propelled by the increasing incidence of neurological disorders and an aging global population, both of which drive the demand for early and precise disease detection. For instance, the World Health Organization reported in 2024 that neurological conditions affected more than one in three people worldwide, underscoring the urgent necessity for specialized diagnostic interventions.

Despite these positive growth drivers, the market encounters significant hurdles due to the high costs associated with acquiring and installing imaging systems. This financial strain is frequently exacerbated by inadequate reimbursement policies and a shortage of skilled radiologists in emerging economies, factors that collectively limit the widespread implementation of these diagnostic tools. Consequently, the substantial capital requirements and workforce constraints continue to pose challenges to the broad adoption of advanced neuroimaging technologies across diverse economic regions.

Market Driver

A primary catalyst for the Global Brain Imaging and Neuroimaging Market is the rising prevalence of neurological and neurodegenerative diseases. As the global population ages, the frequency of central nervous system conditions is increasing, creating a strong demand for advanced diagnostic modalities that support early intervention. According to the American Cancer Society's January 2025 estimates, approximately 24,820 malignant brain or spinal cord tumors were expected to be diagnosed in the United States that year. This persistent disease burden necessitates the widespread use of high-resolution imaging systems like MRI and CT to assess structural integrity and guide treatment strategies, thereby sustaining market adoption.

Simultaneously, rapid technological progress and the integration of artificial intelligence into diagnostic workflows are significantly fueling market expansion. AI-enabled software has transformed neuroimaging by accelerating image reconstruction, enhancing diagnostic precision, and facilitating automated anomaly detection. As reported by AuntMinnie in July 2025, the FDA listed 211 AI-enabled medical devices cleared between September 2024 and July 2025, with radiology software accounting for 81% of these approvals. These innovations are further supported by substantial investment in research and development; The Transmitter noted in November 2025 that National Institutes of Health (NIH) funding for neuroscience projects reached $10.5 billion in 2024, creating an environment that fosters continuous innovation in brain imaging technologies.

Market Challenge

The substantial costs involved in acquiring and installing imaging systems present a formidable barrier to the growth of the Global Brain Imaging and Neuroimaging Market. Sophisticated diagnostic modalities, such as magnetic resonance imaging and computed tomography, require heavy capital expenditure that covers not only the initial purchase price but also expensive infrastructure modifications and specialized maintenance. This financial magnitude limits market penetration, particularly in smaller healthcare facilities and developing regions where budget constraints are severe. Consequently, many institutions are forced to extend the lifecycle of obsolete equipment rather than investing in modern neuroimaging technologies.

This economic pressure is further intensified by the declining financial stability of healthcare providers, which directly hinders the procurement of new equipment. According to the American Hospital Association, the number of days of cash on hand for hospitals and health systems dropped by 28.3% in 2024 compared to the start of 2022, severely restricting their ability to invest in new medical technology and infrastructure. This reduction in liquidity compels hospitals to deprioritize high-cost imaging investments, thereby directly slowing down revenue growth and adoption rates within the global neuroimaging sector.

Market Trends

The adoption of portable and point-of-care MRI systems is reshaping the market by moving neuroimaging from traditional radiology suites to critical care units and remote environments. This shift meets the urgent need for immediate stroke diagnosis and brain monitoring in patients who cannot be safely transported to high-field magnets, effectively overcoming infrastructure hurdles such as the requirement for radiofrequency shielding. As reported by Hyperfine, Inc. in March 2025, the company sold 48 commercial Swoop portable MRI systems in 2024, resulting in a 17% revenue increase driven by growing hospital adoption. These low-field, wheeled systems remove the need for specialized facilities, thereby democratizing access to neuroimaging and enabling faster clinical decision-making directly at the patient's bedside.

Additionally, the emergence of helium-free and liquid-free MRI technology is gaining momentum as healthcare providers seek to lower operational risks associated with global helium shortages and complex quench pipe infrastructure. This trend involves the deployment of sealed magnet technologies that utilize negligible amounts of coolant, significantly reducing lifecycle costs and siting complexities compared to conventional wet magnets. According to a November 2025 press release from Royal Philips, the company has installed over 2,000 of its 1.5T BlueSeal helium-free MRI systems globally, saving more than 6 million liters of liquid helium to date. This technological evolution ensures continuous uptime during supply disruptions and supports sustainability goals, establishing helium-free magnets as a resilient standard for future brain imaging installations.

Key Market Players

• Varian Medical Systems
• General Electric Company
• Siemens AG
• Philips Healthcare
• Toshiba Medical Systems
• Hitachi Medical Systems
• Esaote SpA
• Sanrad Medical Systems Pvt. Ltd

Report Scope

In this report, the Global Brain Imaging and Neuroimaging Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Brain Imaging and Neuroimaging Market, By Imaging Type

• Functional Magnetic Resonance Imaging (fMRI)
• Computed Tomography (CT)
• Positron Emission Tomography (PET)
• Electroencephalography (EEG)
• Magnetoencephalography (MEG)
• Near Infrared Spectroscopy (NIRS);

Brain Imaging and Neuroimaging Market, By End User

• Hospitals & Clinics
• Ambulatory Surgical Centers
• Others

Brain Imaging and Neuroimaging Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Brain Imaging and Neuroimaging Market.

Available Customizations:

Global Brain Imaging and Neuroimaging Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Brain Imaging and Neuroimaging Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Imaging Type (Functional Magnetic Resonance Imaging (fMRI), Computed Tomography (CT), Positron Emission Tomography (PET), Electroencephalography (EEG), Magnetoencephalography (MEG), Near Infrared Spectroscopy (NIRS);)
  • 5.2.2. By End User (Hospitals & Clinics, Ambulatory Surgical Centers, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Brain Imaging and Neuroimaging Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Imaging Type
  • 6.2.2. By End User
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Brain Imaging and Neuroimaging Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Imaging Type
      • 6.3.1.2.2. By End User
  • 6.3.2. Canada Brain Imaging and Neuroimaging Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Imaging Type
      • 6.3.2.2.2. By End User
  • 6.3.3. Mexico Brain Imaging and Neuroimaging Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Imaging Type
      • 6.3.3.2.2. By End User

7. Europe Brain Imaging and Neuroimaging Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Imaging Type
  • 7.2.2. By End User
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Brain Imaging and Neuroimaging Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Imaging Type
      • 7.3.1.2.2. By End User
  • 7.3.2. France Brain Imaging and Neuroimaging Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Imaging Type
      • 7.3.2.2.2. By End User
  • 7.3.3. United Kingdom Brain Imaging and Neuroimaging Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Imaging Type
      • 7.3.3.2.2. By End User
  • 7.3.4. Italy Brain Imaging and Neuroimaging Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Imaging Type
      • 7.3.4.2.2. By End User
  • 7.3.5. Spain Brain Imaging and Neuroimaging Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Imaging Type
      • 7.3.5.2.2. By End User

8. Asia Pacific Brain Imaging and Neuroimaging Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Imaging Type
  • 8.2.2. By End User
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Brain Imaging and Neuroimaging Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Imaging Type
      • 8.3.1.2.2. By End User
  • 8.3.2. India Brain Imaging and Neuroimaging Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Imaging Type
      • 8.3.2.2.2. By End User
  • 8.3.3. Japan Brain Imaging and Neuroimaging Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Imaging Type
      • 8.3.3.2.2. By End User
  • 8.3.4. South Korea Brain Imaging and Neuroimaging Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Imaging Type
      • 8.3.4.2.2. By End User
  • 8.3.5. Australia Brain Imaging and Neuroimaging Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Imaging Type
      • 8.3.5.2.2. By End User

9. Middle East & Africa Brain Imaging and Neuroimaging Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Imaging Type
  • 9.2.2. By End User
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Brain Imaging and Neuroimaging Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Imaging Type
      • 9.3.1.2.2. By End User
  • 9.3.2. UAE Brain Imaging and Neuroimaging Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Imaging Type
      • 9.3.2.2.2. By End User
  • 9.3.3. South Africa Brain Imaging and Neuroimaging Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Imaging Type
      • 9.3.3.2.2. By End User

10. South America Brain Imaging and Neuroimaging Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Imaging Type
  • 10.2.2. By End User
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Brain Imaging and Neuroimaging Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Imaging Type
      • 10.3.1.2.2. By End User
  • 10.3.2. Colombia Brain Imaging and Neuroimaging Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Imaging Type
      • 10.3.2.2.2. By End User
  • 10.3.3. Argentina Brain Imaging and Neuroimaging Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Imaging Type
      • 10.3.3.2.2. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Brain Imaging and Neuroimaging Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Varian Medical Systems
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. General Electric Company
• 15.3. Siemens AG
• 15.4. Philips Healthcare
• 15.5. Toshiba Medical Systems
• 15.6. Hitachi Medical Systems
• 15.7. Esaote SpA
• 15.8. Sanrad Medical Systems Pvt. Ltd

16. Strategic Recommendations

17. About Us & Disclaimer